Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Latest News
Image of two researchers looking into microscopes
Facilities & CapacityAragen $100m PE boost to bolster CDMO ambition in India and beyond
Aragen $100m PE boost to bolster CDMO ambition in India and beyond
Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.
Deal-Making
Iconovo taps Lonza for spray-dried obesity biologicIconovo taps Lonza for spray-dried obesity biologic
Lonza joins the race for weight loss drugs with plans to produce an active pharmaceutical ingredient (API) for Iconovo’s intranasal biologic.
Deal-Making
Samsung Bio lands $1.4bn contract with undisclosed EU clientSamsung Bio lands $1.4bn contract with undisclosed EU client
Contract development and manufacturing organization (CDMO) Samsung Biologics will provide manufacturing services for the client in what it calls its ‘largest ever contract’.
Facilities & Capacity
Gilead cites manufacturing efficiencies as CAR-T advantage in 2025Gilead cites manufacturing efficiencies as CAR-T advantage in 2025
Company experts pointed to fast turnaround time as key to successfully launching a new autologous therapy in 2026.
Therapeutic Class
Casgevy and beyond: Allogeneic therapies take spotlight for CRISPR TherapeuticsCasgevy and beyond: Allogeneic therapies take spotlight for CRISPR Therapeutics
The CEO of CRISPR Therapeutics gave attendees a peek into the future of off-the-shelf gene therapies at the JP Morgan conference in San Francisco, California.
Global Markets
Samsung Bio lands $1.4bn contract with undisclosed EU clientSamsung Bio lands $1.4bn contract with undisclosed EU client
Contract development and manufacturing organization (CDMO) Samsung Biologics will provide manufacturing services for the client in what it calls its ‘largest ever contract’.
Facilities & Capacity
Aragen $100m PE boost to bolster CDMO ambition in India and beyondAragen $100m PE boost to bolster CDMO ambition in India and beyond
Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.
Regulations
Department of Commerce cracks down on biotechnology exportsDepartment of Commerce cracks down on biotechnology exports
With BIOSECURE in limbo, the US government seeks other ways to protect American interests.
Facilities & Capacity
Aragen $100m PE boost to bolster CDMO ambition in India and beyondAragen $100m PE boost to bolster CDMO ambition in India and beyond
Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.
Therapeutic Class
Thermo cites Catalent, capacity, and Trumpian tariffs in positive CDMO outlookThermo cites Catalent, capacity, and Trumpian tariffs in positive CDMO outlook
Scaling capacity takes center stage at JPM as Thermo Fisher’s CEO navigates evolving pharma landscape and policy shifts.
Therapeutic Class
Gilead cites manufacturing efficiencies as CAR-T advantage in 2025Gilead cites manufacturing efficiencies as CAR-T advantage in 2025
Company experts pointed to fast turnaround time as key to successfully launching a new autologous therapy in 2026.
Upstream & Downstream Processing
Department of Commerce cracks down on biotechnology exportsDepartment of Commerce cracks down on biotechnology exports
With BIOSECURE in limbo, the US government seeks other ways to protect American interests.
Therapeutic Class
Gilead cites manufacturing efficiencies as CAR-T advantage in 2025Gilead cites manufacturing efficiencies as CAR-T advantage in 2025
Company experts pointed to fast turnaround time as key to successfully launching a new autologous therapy in 2026.